494 related articles for article (PubMed ID: 37448448)
1. Imlifidase for Kidney Transplantation of Highly Sensitized Patients With a Positive Crossmatch: The French Consensus Guidelines.
Couzi L; Malvezzi P; Amrouche L; Anglicheau D; Blancho G; Caillard S; Freist M; Guidicelli GL; Kamar N; Lefaucheur C; Mariat C; Koenig A; Noble J; Thaunat O; Thierry A; Taupin JL; Bertrand D
Transpl Int; 2023; 36():11244. PubMed ID: 37448448
[TBL] [Abstract][Full Text] [Related]
2. Highly Sensitized Patients: Miami Transplant Institute Experience.
Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
[TBL] [Abstract][Full Text] [Related]
3. Imlifidase therapy: exploring its clinical uses.
Rostaing L; Noble J; Malvezzi P; Jouve T
Expert Opin Pharmacother; 2023 Feb; 24(2):259-265. PubMed ID: 36404277
[TBL] [Abstract][Full Text] [Related]
4. Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes).
Jordan SC; Legendre C; Desai NM; Lorant T; Bengtsson M; Lonze BE; Vo AA; Runström A; Laxmyr L; Sjöholm K; Schiött Å; Sonesson E; Wood K; Winstedt L; Kjellman C; Montgomery RA
Transplantation; 2021 Aug; 105(8):1808-1817. PubMed ID: 33093408
[TBL] [Abstract][Full Text] [Related]
5. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
[TBL] [Abstract][Full Text] [Related]
7. One-Year Outcomes of Living Related Kidney Transplant in Patients With Preformed HLA Donor-Specific Antibodies: A Single-Center Experience in Malaysia.
Jalalonmuhali M; Ng KP; Mohd Shariff NH; Lee YW; Wong AH; Gan CC; Lim SK
Transplant Proc; 2020; 52(6):1718-1722. PubMed ID: 32448671
[TBL] [Abstract][Full Text] [Related]
8. Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants.
Sharma A; King A; Kumar D; Behnke M; McDougan F; Kimball PM
Prog Transplant; 2016 Jun; 26(2):157-61. PubMed ID: 27207404
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of virtual crossmatch (VXM) prediction of physical crossmatch (PXM) results of donor specific antibody (DSA) in routine pretransplant settings-a single-center experience.
Olszowska-Zaremba N; Zagożdżon R; Gozdowska J
Transpl Immunol; 2022 Jun; 72():101583. PubMed ID: 35314352
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Donor-Specific Anti-Human Leukocyte Antigen (HLA) Antibody Rebound on the Risk of Antibody Mediated Rejection in Sensitized Kidney Transplant Recipients.
Lee KW; Park JB; Cho CW; Lee N; Yoo H; Kim K; Park H; Kang ES; Huh W; Kim S
Ann Transplant; 2017 Mar; 22():166-176. PubMed ID: 28348361
[TBL] [Abstract][Full Text] [Related]
11. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
[TBL] [Abstract][Full Text] [Related]
12. Low-MFI (median fluorescence intensity) pre-transplant DSA (donor specific antibodies) leading to anamnestic antibody mediated rejection in live-related donor kidney transplantation.
Chauhan R; Tiwari AK; Aggarwal G; Gowri Suresh L; Kumar M; Bansal SB
Transpl Immunol; 2023 Dec; 81():101931. PubMed ID: 37730185
[TBL] [Abstract][Full Text] [Related]
13. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
[TBL] [Abstract][Full Text] [Related]
14. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation.
Bingaman AW; Murphey CL; Palma-Vargas J; Wright F
Transplantation; 2008 Dec; 86(12):1864-8. PubMed ID: 19104435
[TBL] [Abstract][Full Text] [Related]
15. Imlifidase Desensitization in HLA-incompatible Kidney Transplantation: Finding the Sweet Spot.
de Weerd AE; Roelen DL; van de Wetering J; Betjes MGH; Heidt S; Reinders MEJ
Transplantation; 2024 Feb; 108(2):335-345. PubMed ID: 37340532
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
17. Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.
Kjellman C; Maldonado AQ; Sjöholm K; Lonze BE; Montgomery RA; Runström A; Lorant T; Desai NM; Legendre C; Lundgren T; von Zur Mühlen B; Vo AA; Olsson H; Jordan SC
Am J Transplant; 2021 Dec; 21(12):3907-3918. PubMed ID: 34236770
[TBL] [Abstract][Full Text] [Related]
18. IdeS (Imlifidase): A Novel Agent That Cleaves Human IgG and Permits Successful Kidney Transplantation Across High-strength Donor-specific Antibody.
Lonze BE; Tatapudi VS; Weldon EP; Min ES; Ali NM; Deterville CL; Gelb BE; Benstein JA; Dagher NN; Wu M; Montgomery RA
Ann Surg; 2018 Sep; 268(3):488-496. PubMed ID: 30004918
[TBL] [Abstract][Full Text] [Related]
19. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
Yuan XP; Wang CX; Gao W; Fu Q; He XS
Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
[TBL] [Abstract][Full Text] [Related]
20. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
